Leading the Way in Life Science Technologies

GEN Exclusives

More »

GEN News Highlights

More »
June 10, 2008

OncoMethylome to Help Merck KGaA Advance Glioblastoma Multiforme Drug Evaluation

  • OncoMethylome Sciences will provide MGMT gene-promoter methylation testing services for Merck KGaA’s clinical trial program of cilengitide.

    As part of the agreement, Merck received a worldwide, nonexclusive license to use the results for optimizing glioblastoma multiforme (GBM) treatment with cilengitide.

  • You’re all set! Thank you for subscribing to GEN Highlights.